PayTM(Rs. 673.34 crore), HDFC Bank(Rs. 628.41 crore), Aegis Logistics(Rs. 548.06 crore), Dr. Reddys(Rs. 508.47 crore), Kalyan ...

Dr. Reddy’s Laboratories shares fell by 6.2%, hitting an intraday low of Rs 1,209.70 on the BSE on Friday, January 24, ...

Shares of Dr Reddy's Laboratories Ltd tumbled more than 6.65 per cent to Rs 1,203.60 on Friday, with its total market capitalisation slipping below Rs 1 lakh crore mark.

The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.

Dr. Reddy's Laboratories shares in Friday's trade slipped by over 6 per cent in early trade to the day's low price of Rs 1,203.6 after the pharma major posted weak performance during the December ...

Extending losses for the second session, Dr Reddy’s shares dropped 6.65% to hit a low of ₹1,203.60 on the BSE as investors weighed weak Q3 results.

(Reuters) -Indian shares gave up opening gains to inch lower on Friday, as worries over moderation in corporate earnings ...

Indian benchmark indices opened higher on Friday, extending gains to day three this week, as Nifty Bank, auto, FMCG and IT sectors led the morning trade. In early trade, Nifty rose 0.31 per cent to 23 ...

Dr. Reddy's Laboratories shares fell by 6.2% after the company reported a marginal 2% YoY growth in Q3 FY25 net profit to Rs 1,413 crore. Despite robust revenue growth, Jefferies, Nuvama, and DAM ...

Revlimid is a medicine used to treat certain cancers and serious conditions affecting blood cells and bone marrow.

Dr Reddy’s shares tumbled up to 6% in early trade and at 9:46 am, they were trading 4.35% lower at Rs 1,233.25 on the Bombay Stock Exchange (BSE).

Dr. Reddy's shares are the top losers on the Nifty 50 index today. Out of the 40 analysts that have coverage on Dr. Reddy's, 15 of them have a 'Buy' rating, while 15 of them have a 'Sell' call. The ...